NasdaqGS:DFTXPharmaceuticals
Will New GAD Treatment Persistence Data Change Definium Therapeutics' (DFTX) Unmet‑Need Narrative?
Definium Therapeutics recently reported results from a large U.S. healthcare claims study, published in CNS Spectrums, examining real‑world pharmacotherapy patterns in adults with generalized anxiety disorder between 2020 and 2024.
The analysis revealed frequent early discontinuation, rapid switching, and prolonged gaps in care, underscoring substantial unmet need and limited durability of benefit with current GAD treatment options.
Next, we will explore how this evidence of high...